Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Nov 23, 2022--
The "Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global monoclonal antibodies market size reached US$ 194.03 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 304.16 Billion by 2027, exhibiting a CAGR of 7.78% during 2021-2027.
Companies Mentioned
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Monoclonal antibodies (mAbs) are laboratory-produced proteins used to serve as substitute antibodies that can enhance, modify, restore, and mimic the attack of the immune system on unwanted cells. They are utilized for detecting and targetting cancer cells for destruction by enhancing the immune system.
They are also employed to block the connection between a cancer cell and proteins that promote cell growth. In addition, they prevent the formation of proteins for enabling immune system cells to work efficiently against cancer cells. Besides this, mAbs transport the radiation treatment directly to cancer cells and minimize the effect of radiation on healthy cells.
At present, the growing prevalence of chronic diseases, such as cancer, heart disease, stroke, diabetes, and arthritis, represents one of the key factors driving the market. Besides this, leading manufacturers are extensively investing in research and development (R&D) activities to introduce enhanced mAb drugs for treating neurodegenerative diseases, such as Alzheimer's, Huntington's, Parkinson's, and Lewy body diseases.
They are also focusing on various marketing strategies to expand their customer base, which is contributing to the growth of the market. In addition, the increasing demand for humanized mAbs to treat various antigens, such as cancer cells, immunosuppression, and immunomodulatory molecules, are offering lucrative growth opportunities to industry investors. Apart from this, there is a rise in the demand for cost-efficient biosimilar mAbs to treat cancer across the globe. This, along with the burgeoning healthcare industry, is propelling the growth of the market.
Moreover, technological advancements in various genetic platforms, such as next-generation sequencing, is offering a positive market outlook. Additionally, there is an increase in the employment of advanced genetic engineering technology in mAbs production around the world. This, coupled with the rising awareness among the masses about the benefits of mAb therapy, is bolstering the market growth.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global monoclonal antibodies market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on production method, source, indication and end use.
Breakup by Production Method:
Breakup by Source:
Breakup by Indication:
Breakup by End Use:
Breakup by Region:
Key Questions Answered in This Report:
For more information about this report visit https://www.researchandmarkets.com/r/nzksvr
View source version on businesswire.com:https://www.businesswire.com/news/home/20221123005290/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 11/23/2022 08:49 AM/DISC: 11/23/2022 08:49 AM
http://www.businesswire.com/news/home/20221123005290/en